Page last updated: 2024-11-05

rhenium

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Rhenium is a chemical element with the symbol Re and atomic number 75. It is a silvery-gray, hard, dense, and corrosion-resistant transition metal in group 7 of the periodic table. Rhenium is found in trace amounts in minerals such as molybdenite and is recovered as a byproduct of molybdenum mining. It is also found in some platinum ores. Rhenium has the highest melting point (3186 °C) of all elements and has the second-highest boiling point (5596 °C) after only tungsten. It is also resistant to corrosion by acids and alkalis. Rhenium is used in a variety of applications, including: * High-temperature alloys, such as those used in jet engines and other aerospace applications. * Electrical contacts, due to its excellent electrical conductivity and resistance to wear. * Catalysts, particularly in the production of gasoline and other chemicals. * Superalloys, where it is used to improve the strength and resistance of the alloy to high temperatures and corrosion. * Medical imaging, in the form of rhenium-186 and rhenium-188 isotopes, which are used for diagnosis and treatment of various conditions. Rhenium is studied for its potential applications in a variety of fields, including: * Nanoelectronics, due to its excellent electrical properties. * Biomedical applications, such as the development of targeted drug delivery systems. * Catalysis, for the development of new and more efficient catalytic processes. * Energy storage, for the development of high-energy density batteries. Rhenium is a relatively rare element, but it is important for a variety of applications. It is also a valuable commodity, and its price is influenced by supply and demand factors.'

Rhenium: A metal, atomic number 75, atomic weight 186.207, symbol Re. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID23947
CHEBI ID49882
MeSH IDM0019004

Synonyms (154)

Synonym
einecs 231-124-5
rhenium, elementar
Q737
RE ,
rhenium
nsc-600662
rhenium, foil, thickness 1.0 mm, 99.98% trace metals basis
rhenium, rod, l 25 mm, diam. 4 mm, 99.99% trace metals basis
rhenium, powder, 99.995% trace metals basis
rhenium, foil, thickness 0.1 mm, 99.98% trace metals basis
rhenium, foil, thickness 0.25 mm, 99.98% trace metals basis
rhenium, powder, -100 mesh, >=99.9% trace metals basis
rhenium, wire, diam. 1.0 mm, >=99.9% trace metals basis
rhenium, foil, thickness 0.025 mm, 99.98% trace metals basis
CHEBI:49882
75re
7440-15-5
renio
rhenium atom
rhenium ion(re7 )
rhenium, ion(re7 )
7yhu292iny ,
ec 231-124-5
unii-7yhu292iny
AKOS015914602
rhenium element
rhenium, elemental
rhenium [mi]
WUAPFZMCVAUBPE-UHFFFAOYSA-N
rhenium-on-carbon
DTXSID9064685
rhenium slug, 12.7mm (0.5in) dia
rhenium wire, 0.25mm (0.01in) dia
rhenium foil, 0.25mm (0.01in) thick
rhenium powder, -325 mesh
rhenium foil, 1.0mm (0.04in) thick
rhenium foil, 0.5mm (0.02in) thick, annealed
rhenium foil, 0.025mm (0.001in) thick
rhenium wire, 0.5mm (0.02in) dia
rhenium wire, 0.1mm (0.004in) dia
rhenium rod, 4.7-5mm (0.19-0.2in) dia
rhenium powder, -22 mesh, puratronic?
rhenium foil, 0.1mm (0.004in) thick
rhenium wire, 1.0mm (0.04in) dia
rhenium standard for aas, analytical standard, ready-to-use, in nitric acid
mfcd00011195
rhenium wire
rhenium powder
rhenium pellets
rhenium foil
rhenium metal powder
rhenium, foil, thickness 1.0 mm, size 25 x 25 mm, purity 99.99%
rhenium, foil, thickness 0.05 mm, length 0.1 m, coil width 0.76 mm
rhenium, foil, thickness 0.04 mm, length 0.2 m, coil width .7 mm
rhenium, wire reel, 0.2m, diameter 1.0mm, annealed, 99.97%
rhenium, wire reel, 0.5m, diameter 0.3mm, annealed, 99.97%
rhenium, foil, thickness 0.05 mm, size 25 x 25 mm, purity 99.99%
rhenium, wire reel, 0.5m, diameter 0.10mm, annealed, 99.97%
rhenium, foil, thickness 0.04 mm, length 0.5 m, coil width .8 mm
rhenium, wire reel, 0.5m, diameter 0.5mm, annealed, 99.97%
rhenium, wire reel, 0.1m, diameter 0.5mm, annealed, 99.97%
rhenium, wire reel, 0.1m, diameter 0.2mm, annealed, 99.97%
rhenium, wire reel, 0.2m, diameter 0.076mm, annealed, 99.97%
rhenium, wire reel, 1m, diameter 0.125mm, annealed, 99.97%
rhenium, foil, thickness 0.025 mm, length 2 m, coil width 0.76 mm
rhenium, foil, thickness 0.025 mm, length 5 m, coil width 0.76 mm
rhenium, foil, thickness 0.03 mm, length 0.1 m, coil width 0.76 mm
rhenium, foil, thickness 0.035 mm, length 0.1 m, coil width 0.76 mm
rhenium, foil, thickness 0.25 mm, size 25 x 25 mm, purity 99.99%
rhenium, foil, thickness 0.025 mm, length 0.2 m, coil width 0.76 mm
rhenium, foil, thickness 0.125 mm, size 25 x 25 mm, purity 99.99%
rhenium, wire reel, 1m, diameter 0.178mm, annealed, 99.97%
rhenium, wire reel, 2m, diameter 0.25mm, annealed, 99.97%
rhenium, foil, thickness 0.035 mm, length 0.05 m, coil width 0.76 mm
rhenium, wire reel, 0.2m, diameter 0.10mm, annealed, 99.97%
rhenium, foil, thickness 0.025 mm, size 25 x 25 mm, tolerance 0.25
rhenium, wire reel, 0.5m, diameter 0.178mm, annealed, 99.97%
rhenium, rod, 1.5 mm diameter, length 25 mm, purity 99.99%
rhenium, foil, thickness 0.5 mm, size 25 x 25 mm, purity 99.99%
rhenium, foil, thickness 1.0 mm, diameter 12 mm, purity 99.99%
rhenium, wire reel, 2m, diameter 0.2mm, annealed, 99.97%
rhenium, wire reel, 0.2m, diameter 0.15mm, annealed, 99.97%
rhenium, wire reel, 0.5m, diameter 0.15mm, annealed, 99.97%
rhenium, wire reel, 0.5m, diameter 0.125mm, annealed, 99.97%
rhenium, foil, thickness 0.025 mm, length 1 m, coil width 0.76 mm
rhenium, foil, thickness 0.03 mm, length 0.2 m, coil width 0.76 mm
rhenium, foil, thickness 0.04 mm, length 2 m, coil width .7 mm
rhenium, foil, thickness 0.025 mm, length 0.5 m, coil width 0.76 mm
rhenium, powder, max. particle size 45 micron, weight 5 g, purity 99.99%
rhenium, foil, thickness 0.035 mm, length 0.5 m, coil width 0.76 mm
rhenium, wire reel, 0.2m, diameter 0.2mm, annealed, 99.97%
rhenium, wire reel, 0.5m, diameter 0.076mm, annealed, 99.97%
rhenium, wire reel, 1m, diameter 0.25mm, annealed, 99.97%
rhenium, wire reel, 0.1m, diameter 0.15mm, annealed, 99.97%
rhenium, foil, thickness 0.04 mm, length 0.2 m, coil width .8 mm
rhenium, wire reel, 0.1m, diameter 0.076mm, annealed, 99.97%
rhenium, wire reel, 0.2m, diameter 0.5mm, annealed, 99.97%
rhenium, wire reel, 0.2m, diameter 0.3mm, annealed, 99.97%
rhenium, foil, thickness 0.025 mm, length 0.1 m, coil width 0.76 mm
rhenium, wire reel, 0.1m, diameter 0.3mm, annealed, 99.97%
rhenium, wire reel, 2m, diameter 0.178mm, annealed, 99.97%
rhenium, wire reel, 0.1m, diameter 0.178mm, annealed, 99.97%
rhenium, foil, thickness 0.03 mm, length 0.5 m, coil width 0.76 mm
rhenium, foil, thickness 0.0125 mm, size 25 x 25 mm, purity 99.99%
rhenium, wire reel, 0.025m, diameter 1.0mm, annealed, 99.97%
rhenium, wire reel, 0.1m, diameter 0.125mm, annealed, 99.97%
rhenium, wire reel, 0.05m, diameter 0.5mm, annealed, 99.97%
rhenium, wire reel, 1m, diameter 0.15mm, annealed, 99.97%
rhenium, foil, thickness 0.035 mm, length 0.2 m, coil width 0.76 mm
rhenium, foil, thickness 0.20 mm, size 25 x 25 mm, purity 99.99%
rhenium, wire reel, 0.1m, diameter 0.10mm, annealed, 99.97%
rhenium, foil, thickness 0.03 mm, length 2 m, coil width 0.76 mm
rhenium, wire reel, 1m, diameter 0.2mm, annealed, 99.97%
rhenium, powder, 45 max. part. size (micron), weight 10 g, purity 99.99%
rhenium, wire reel, 2m, diameter 0.125mm, annealed, 99.97%
rhenium, foil, thickness 0.05 mm, length 1 m, coil width 0.76 mm
rhenium, wire reel, 2m, diameter 0.15mm, annealed, 99.97%
rhenium, foil, thickness 0.04 mm, length 1 m, coil width .7 mm
rhenium, wire reel, 0.1m, diameter 0.25mm, annealed, 99.97%
rhenium, foil, thickness 0.05 mm, length 0.5 m, coil width 0.76 mm
rhenium, foil, thickness 0.04 mm, length 1 m, coil width .8 mm
rhenium, foil, thickness 0.15 mm, size 25 x 25 mm, purity 99.99%
rhenium, wire reel, 1m, diameter 0.10mm, annealed, 99.97%
rhenium, foil, thickness 0.04 mm, length 2 m, coil width .8 mm
rhenium, wire reel, 1m, diameter 0.3mm, annealed, 99.97%
rhenium, rod, length 100 mm, 1.5 mm diameter, purity 99.99%
rhenium, foil, thickness 0.05 mm, length 2 m, coil width 0.76 mm
rhenium, foil, thickness 0.05 mm, length 0.2 m, coil width 0.76 mm
rhenium, wire reel, 1m, diameter 0.076mm, annealed, 99.97%
rhenium, wire reel, 0.5m, diameter 0.2mm, annealed, 99.97%
rhenium, foil, thickness 0.04 mm, length 0.5 m, coil width .7 mm
rhenium, wire reel, 0.2m, diameter 0.178mm, annealed, 99.97%
rhenium, foil, thickness 0.03 mm, length 1 m, coil width 0.76 mm
rhenium, foil, thickness 0.04 mm, length 0.1 m, coil width .7 mm
rhenium, wire reel, 0.5m, diameter 0.25mm, annealed, 99.97%
rhenium, rod, 1.5 mm diameter, length 50 mm, purity 99.99%
rhenium, wire reel, 0.2m, diameter 0.25mm, annealed, 99.97%
rhenium, wire reel, 0.2m, diameter 0.125mm, annealed, 99.97%
rhenium, wire reel, 0.1m, diameter 1.0mm, annealed, 99.97%
rhenium, wire reel, 0.05m, diameter 1.0mm, annealed, 99.97%
rhenium, foil, thickness 0.04 mm, length 0.1 m, coil width .8 mm
rhenium hydride
rhenium(iii) hydride
rhenium powder (99.99%) puratrem
rhenium pentahydride
rhenium nanorods
rhenium nanofoil
rhenium nanoprisms
strontium cobalt oxide (srcoo3) sputtering targets
rhenium, powder 22 mesh
EN300-7565166
rhenium standard: re @ 1000 microg/ml in 5% hno3
rhenium standard: re @ 10000 microg/ml in 5% hno3
rhenium - re @ 1000 microg/ml in 5% hno3

Research Excerpts

Overview

Rhenium is an element that exhibits a broad range of oxidation states. Rhenium-HEDP is an effective bone-targeting therapeutic radiopharmaceutical, for treatment of osteoblastic bone metastases.

ExcerptReferenceRelevance
"Rhenium-188 (Re) is a β, γ emitter and considered a theranostic radionuclide. "( Concentration protocol of rhenium-188 perrhenate eluted from tungsten-188/rhenium-188 generator for the preparation of high-yield rhenium-188-labelled radiopharmaceuticals.
Bhusari, P; Chhabra, A; Mittal, BR; Rathore, Y; Shukla, J; Vatsa, R, 2018
)
2.22
"Rhenium is an element that exhibits a broad range of oxidation states. "( Rhenium(VII) Compounds as Inorganic Precursors for the Synthesis of Organic Reaction Catalysts.
Benke, G; Ciszewski, M; Drzazga, M; Kopyto, D; Kowalik, P; Kula, B; Leszczyńska-Sejda, K; Malarz, J; Piątek, J; Zemlak, K, 2019
)
3.4
"(188)Rhenium-HEDP is an effective bone-targeting therapeutic radiopharmaceutical, for treatment of osteoblastic bone metastases. "( Drug composition matters: the influence of carrier concentration on the radiochemical purity, hydroxyapatite affinity and in-vivo bone accumulation of the therapeutic radiopharmaceutical 188Rhenium-HEDP.
Beekman, FJ; Bloemendal, HJ; de Klerk, JMH; Hendrikse, NH; Lange, R; Ramakers, RM; Ter Heine, R; van der Westerlaken, MML, 2015
)
1.12
"Rhenium-188 (188Re) is a high energy beta-emitter with a physical half life of 17 hours. "( Rhenium-188 based radiopharmaceuticals for treatment of liver tumours.
Bacher, K; Defreyne, L; Lambert, B, 2009
)
3.24
"Rhenium-186 is a beta-emitting radionuclide that has been studied for applications in radioimmunotherapy. "( Dosimetry of rhenium-186-labeled monoclonal antibodies: methods, prediction from technetium-99m-labeled antibodies and results of phase I trials.
Abrams, PG; Beaumier, PL; Bjorn, MJ; Breitz, HB; Durham, JS; Fisher, DR; Ratliff, BA; Weiden, PL, 1993
)
2.1
"Rhenium-188 (188Re) is a high-energy beta-emitter that is routinely available from a 188W/188Re generator in liquid form."( Pharmacokinetics of 99Tcm-pertechnetate and 188Re-perrhenate after oral administration of perchlorate: option for subsequent care after the use of liquid 188Re in a balloon catheter.
Fenchel, S; Guhlmann, A; Knapp, FF; Kotzerke, J; Rentschler, M; Reske, SN; Stabin, M, 1998
)
1.02
"Rhenium (Re)-188 is a generator (W-188/Re-188) produced high energy beta-emitter suitable for radionuclide therapy (T1/2 is 16.9 hrs and Emax 2.1 MeV (range 11 mm)). "( Expression profile of vascular cell adhesion molecule-1 (CD106) in inflammatory foci using rhenium-188 labelled monoclonal antibody in mice.
Kairemo, KJ; Karonen, SL; Nikula, TK; Strömberg, S, 1998
)
1.96
"Rhenium-188 (188Re) is an important therapeutic radioisotope which is obtained on demand as carrier-free sodium perrhenate by saline elution of the tungsten-188/rhenium-188 generator system. "( Rhenium-188--a generator-derived radioisotope for cancer therapy.
Knapp, FF, 1998
)
3.19
"Rhenium is a radionuclide with physical and chemical properties suitable for radioimmunotherapy. "( Clinical experience with rhenium-186-labeled monoclonal antibodies for radioimmunotherapy: results of phase I trials.
Appelbaum, JW; Bjorn, MJ; Breitz, HB; Fer, MF; Foisie, DC; Ratliff, BA; Seiler, CA; Vanderheyden, JL; Weiden, PL; Wolf, SB, 1992
)
2.03

Effects

The rhenium complexes have been tested for competitive inhibition of the (yeast) hexokinase. Rhenium-186 has been determined to be a leading radionuclide for radioimmunotherapy.

ExcerptReferenceRelevance
"Rhenium-188 has a half-life of 16.9 h and maximum beta energy of 2.118 MeV."( 188Re-direct labeling of monoclonal antibodies for radioimmunotherapy of solid tumors: biodistribution, normal organ dosimetry, and toxicology.
Iznaga-Escobar, N, 1998
)
1.02
"The rhenium complexes have been structurally correlated with the technetium complexes by means of HPLC studies."( Tricarbonyltechnetium(I) and tricarbonylrhenium(I) complexes of amino acids: crystal and molecular structure of a novel cyclic dimeric Re(CO)3-amino acid complex comprised of the OON donor atom set of the tridentate ligand.
Baishya, R; Debnath, MC; Halder, KK; Mitra, P; Nayak, DK; Sen, T, 2013
)
1.14
"One rhenium complex has been characterized by X-ray crystallography, and the luminescent properties of [M(CO)3 L(x) (py)](+) are reported."( Rhenium and technetium tricarbonyl complexes of 1,4-Substituted pyridyl-1,2,3-triazole bidentate 'click' ligands conjugated to a targeting RGD peptide.
Ackermann, U; Connell, TU; Donnelly, PS; Hayne, DJ; Tochon-Danguy, HJ; White, JM, 2014
)
2.33
"Rhenium-188 has been used for the preparation of therapeutic radiopharmaceuticals for the management of diseases such as bone metastasis, rheumatoid arthritis and primary cancers."( Rhenium-188: availability from the (188)W/(188)Re generator and status of current applications.
Dash, A; Knapp, FF; Pillai, MR, 2012
)
2.54
"The rhenium complexes have been tested for competitive inhibition of the (yeast) hexokinase."( Synthesis and in vitro characterization of organometallic rhenium and technetium glucose complexes against Glut 1 and hexokinase.
Dumas, C; Garcia-Garayoa, E; Petrig, J; Scapozza, L; Schibli, R; Schubiger, PA; Spadola, L,
)
0.86
"Rhenium-186 has been determined to be a leading radionuclide for radioimmunotherapy. "( Rhenium-186-labeled monoclonal antibodies for radioimmunotherapy: preparation and evaluation.
Damjanov, I; DeFulvio, J; John, E; McDevitt, MR; Thakur, ML, 1993
)
3.17
"The rhenium-bound peptide has been appended to the N termini of receptor binding alpha-melanocyte stimulating hormone (alpha-MSH, NAc-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2) fragments via solid phase peptide synthesis."( Synthesis and characterization of rhenium-complexed alpha-melanotropin analogs.
Giblin, MF; Jurisson, SS; Quinn, TP,
)
0.89
"Rhenium-186 (186Re) has ideal properties for adjuvant radioimmunotherapy (RIT). "( High dose rhenium-186-labeling of monoclonal antibodies for clinical application: pitfalls and solutions.
Roos, JC; Snow, GB; Stroomer, JW; van Dongen, GA; van Gog, FB; Visser, GW, 1997
)
2.14
"Rhenium-188 has a half-life of 16.9 h and maximum beta energy of 2.118 MeV."( 188Re-direct labeling of monoclonal antibodies for radioimmunotherapy of solid tumors: biodistribution, normal organ dosimetry, and toxicology.
Iznaga-Escobar, N, 1998
)
1.02
"Rhenium has two beta-emitting isotopes (186)Re and (188)Re that have potential for use to treat cancer if the complexes can be targeted with sufficient specificity."( Towards new transition metal-based hypoxic selective agents for therapy and imaging.
Blower, PJ; Dilworth, JR; Maurer, RI; Mullen, GD; Reynolds, CA; Zheng, Y, 2001
)
1.03
"Rhenium-186 has been theoretically determined to be among the best therapy radiolabels due to its unique half-life, particulate and gamma emissions and chelation properties. "( Radiolabeled biomolecules with 186Re: potential for radioimmunotherapy.
Quadri, SM; Wessels, BW, 1986
)
1.71

Toxicity

ExcerptReferenceRelevance
" No major adverse effects were observed."( Evaluation of toxicity and efficacy of 186Re-hydroxyethylidene diphosphonate in patients with painful bone metastases of prostate or breast cancer.
Carpentier, P; Caty, A; Depreux, P; Kolesnikov-Gauthier, H; Sulman, C; Vennin, P, 2000
)
0.31
"186Re-HEDP provides safe symptomatic relief of pain in prostate cancer patients."( Evaluation of toxicity and efficacy of 186Re-hydroxyethylidene diphosphonate in patients with painful bone metastases of prostate or breast cancer.
Carpentier, P; Caty, A; Depreux, P; Kolesnikov-Gauthier, H; Sulman, C; Vennin, P, 2000
)
0.31
" It seems, in view of these results, that radioactive synovectomy is safe and gives great benefits to the haemophilic patients."( On the safety of synoviorthesis in haemophilia.
Caviglia, H; Fernandez-Palazzi, F, 2001
)
0.31
" These results indicate that radiolabeled melanin-binding peptides are efficient and safe in treatment of melanoma and could be potentially useful against this tumor."( Radiolabeled melanin-binding peptides are safe and effective in treatment of human pigmented melanoma in a mouse model of disease.
Bryan, RA; Casadevall, A; Dadachova, E; Huang, X; Mints, L; Moadel, T; Nosanchuk, JD; Nosanchuk, JS; Ortiz, G; Revskaya, E; Schweitzer, AD; Zhang, T, 2006
)
0.33
" In this present work, we report on the acute toxicity study of BMEDA in beagles to identify doses causing no adverse effect and doses causing life-threatening toxicity."( Single dose acute toxicity testing for N,N-bis(2-mercaptoethyl)-N',N' diethylethylenediamine in beagles.
Chang, CH; Lee, TW; Liu, SY, 2014
)
0.4
" The results show that replacement of the aqua ligand with thiosulfate renders the complex less toxic most likely by distrupting its cellular entry."( The effect of sodium thiosulfate on cytotoxicity of a diimine Re(I) tricarbonyl complex.
Capper, MS; Enriquez Garcia, A; Gelfand, BS; Jalilehvand, F; Lai, B; Shemanko, CS; Wang, BO, 2021
)
0.62

Pharmacokinetics

ExcerptReferenceRelevance
" Half-life times of 186Re in three blood fractions (whole blood, plasma and plasma water) were 40."( Pharmacokinetics of rhenium-186 after administration of rhenium-186-HEDP to patients with bone metastases.
de Klerk, JM; van Dijk, A; van het Schip, AD; van Rijk, PP; Zonnenberg, BA, 1992
)
0.61
"To label anti-hepatoma monoclonal antibody (mAb) fragment HAb18 F(ab')2 was labeled with 188Re for the pharmacokinetic model of 188Re-HAb18 F(ab')2 and to evaluate its pharmacokinetic parameters in hepatoma-bearing nude mice."( Pharmacokinetics of radioimmunotherapeutic agent of direct labeling mAb 188Re-HAb18.
Bian, HJ; Chen, ZN; Li, J; Lou, C; Zhou, SB, 2002
)
0.31
" The concentrations of (188)Re-HAb18 F(ab')2 were evaluated with a pharmacokinetic 3P97 software."( Pharmacokinetics of radioimmunotherapeutic agent of direct labeling mAb 188Re-HAb18.
Bian, HJ; Chen, ZN; Li, J; Lou, C; Zhou, SB, 2002
)
0.31
" Research on the labeling of biomolecules with the versatile rhenium-188 has contributed to the development of therapeutics with favorable pharmacokinetic and dosimetric properties for cancer treatment."( Pharmacokinetics and dosimetry of 188 Re-pharmaceuticals.
Arteaga de Murphy, C; Ferro-Flores, G, 2008
)
0.59
"Significant differences were found between healthy and hepatoma rats for beta elimination half-life (22."( Therapeutic 188Re-lanreotide: determination of radiopharmacokinetic parameters in rats.
de Murphy, CA; Jung-Cook, H; Molina-Trinidad, EM; Morales-Marquez, JL; Pedraza-Lopez, M; Serrano, GV; Stack, EM, 2010
)
0.36
"(188)Re-lanreotide had a prolonged beta elimination half-life and increased volume of distribution in rats with hepatocellular carcinoma."( Therapeutic 188Re-lanreotide: determination of radiopharmacokinetic parameters in rats.
de Murphy, CA; Jung-Cook, H; Molina-Trinidad, EM; Morales-Marquez, JL; Pedraza-Lopez, M; Serrano, GV; Stack, EM, 2010
)
0.36
" In reported and ongoing studies, the two fac-[(99m)Tc(I)(CO)3(L)](-) analogues with these neutral dangling chains were found to have pharmacokinetic properties very similar to those of fac-[(99m)Tc(I)(CO)3(NTA)](2-)."( Structure and Properties of fac-[Re(I)(CO)3(NTA)](2-) (NTA(3-) = Trianion of Nitrilotriacetic Acid) and fac-[Re(I)(CO)3(L)](n-) Analogues Useful for Assessing the Excellent Renal Clearance of the fac-[(99m)Tc(I)(CO)3(NTA)](2-) Diagnostic Renal Agent.
Abhayawardhana, PL; Klenc, J; Lipowska, M; Marzilli, LG; Taylor, AT, 2015
)
0.42
" We hypothesized that pharmacokinetic processes can be modeled even better by continuous probability distributions (CPD) of rates, using only 1-2 parameters."( New Approaches for Modeling Radiopharmaceutical Pharmacokinetics Using Continuous Distributions of Rates.
Dadachova, E; Shuryak, I, 2015
)
0.42
"Simple CPD models often outperform more complex discrete-rate models on pharmacokinetic data."( New Approaches for Modeling Radiopharmaceutical Pharmacokinetics Using Continuous Distributions of Rates.
Dadachova, E; Shuryak, I, 2015
)
0.42

Compound-Compound Interactions

ExcerptReferenceRelevance
" We primarily investigated the effect of c-myc antisense oligodeoxynucleotides (ASODNs) combined with 188Re radiation therapy on VSMC proliferation in rabbit common iliac arteries injured by the porous balloon catheter to explore the therapeutic potential of the combined therapy for the prevention of restenosis."( The effect of locally delivered c-myc antisense oligonucleotides combined with intravascular brachytherapy of 188Re liquid-filled balloon therapy on vascular smooth muscle cell proliferation in rabbit iliac arteries after injury with a balloon catheter.
Li, JL; Wang, W; Wang, X, 2007
)
0.34
" The primary end-point was to establish the maximum tolerable dose (MTD) of capecitabine when combined with (188)Re-HEDP."( (188)Re-HEDP combined with capecitabine in hormone-refractory prostate cancer patients with bone metastases: a phase I safety and toxicity study.
Bosma, TB; Lam, MG; van Rijk, PP; Zonnenberg, BA, 2009
)
0.35
"Capecitabine may be safely used in combination with (188)Re-HEDP in a dose of 2,500 mg/m(2) per day and 37 MBq/kg, respectively."( (188)Re-HEDP combined with capecitabine in hormone-refractory prostate cancer patients with bone metastases: a phase I safety and toxicity study.
Bosma, TB; Lam, MG; van Rijk, PP; Zonnenberg, BA, 2009
)
0.35
"To determine the therapeutic efficacy of rhenium 186 ((186)Re)-labeled PEGylated liposomal doxorubicin ((186)Re-liposomal doxorubicin) in combination with radiofrequency (RF) ablation of human head and neck squamous cell carcinoma (HNSCC) xenograft in nude rats."( Chemoradionuclide therapy with 186Re-labeled liposomal doxorubicin in combination with radiofrequency ablation for effective treatment of head and neck cancer in a nude rat tumor xenograft model.
Bao, A; Dodd, GD; Goins, BA; McManus, LM; Phillips, WT; Prihoda, TJ; Soundararajan, A, 2011
)
0.64
"This study evaluated a system for local cancer radiotherapy combined with chemotherapy."( Development of in situ forming thermosensitive hydrogel for radiotherapy combined with chemotherapy in a mouse model of hepatocellular carcinoma.
Chiang, PF; Lee, SY; Liang, KS; Luo, TY; Peng, CL; Shieh, MJ; Shih, YH; Tang, IC; Yao, CJ; Yeh, CH, 2013
)
0.39
" Fifty-eight patients (median age, 67 years; range, 54 to 76) received radioimmunotherapy followed by fludarabine 150 mg/m(2) and busulfan 8 mg/kg combined with either 75 mg (n = 26) or 50 mg (n = 32) alemtuzumab."( Reduced-Intensity Conditioning Combined with (188)Rhenium Radioimmunotherapy before Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia: The Role of In Vivo T Cell Depletion.
Bornhäuser, M; Ehninger, G; Kotzerke, J; Schetelig, J; Schneider, S; Strumpf, A; Wunderlich, G, 2015
)
0.67
" IL-C225 combined with doxorubicin and Re-188 ((188)Re-DXR-IL-C225) was synthesized, and the cytotoxic effects of (188)Re-DXR-IL-C225 were analyzed in EGFR(+) cancer cells using cell viability assays."( Cytotoxic Effects of PEGylated Anti-EGFR Immunoliposomes Combined with Doxorubicin and Rhenium-188 Against Cancer Cells.
Cheng, CN; Hsu, WC; Hwang, JJ; Lee, TW, 2015
)
0.64

Bioavailability

ExcerptReferenceRelevance
" These results suggest that the long circulation and prolonged bioavailability of [(186)Re]Doxil could potentially deliver high concentrations of both doxorubicin and (186)Re to tumor when encapsulated in the same liposome vehicle."( [(186)Re]Liposomal doxorubicin (Doxil): in vitro stability, pharmacokinetics, imaging and biodistribution in a head and neck squamous cell carcinoma xenograft model.
Bao, A; Goins, BA; Perez, R; Phillips, WT; Soundararajan, A, 2009
)
0.35
" The pharmacokinetics of (188)Re-liposomes showed high circulation time and high bioavailability (mean residence time [MRT] = 19."( Biodistribution and pharmacokinetics of 188Re-liposomes and their comparative therapeutic efficacy with 5-fluorouracil in C26 colonic peritoneal carcinomatosis mice.
Chang, CH; Chang, TJ; Chang, YJ; Chen, LC; Ho, CL; Hsu, CW; Lan, KL; Lee, TW; Lee, WC; Liu, IH; Ni, HC; Ting, G; Tsai, CC; Wu, YH, 2011
)
0.37
" Pharmacokinetics of (188)Re-liposome showed the properties of high circulation time and high bioavailability (mean residence time [MRT]=18."( Comparative therapeutic efficacy of rhenium-188 radiolabeled-liposome and 5-fluorouracil in LS-174T human colon carcinoma solid tumor xenografts.
Chang, CH; Chang, YJ; Chen, LC; Hsu, CW; Lan, KL; Lee, TW; Ting, G, 2012
)
0.65

Dosage Studied

ExcerptRelevanceReference
" Thus, in this nonoptimal radioimmunotherapy model, significant antitumor responses were observed using a mildly toxic multiple dosing regimen."( 186Re radioimmunotherapy of small cell lung carcinoma xenografts in nude mice.
Abrams, PG; Beaumier, PL; Burgua, WD; Fritzberg, AR; Kunz, LL; Morgan, AC; Vanderheyden, JL; Venkatesan, P, 1991
)
0.28
" The dosage of these substances also depends on the size of the joint."( [Synoviorthese].
Gallacchi, G; Müller, W, 1982
)
0.26
"Using this relation, it is possible to predict thrombocytopenia by pretreatment bone scintigraphy and to adjust the dosage to each patient to avoid unacceptable toxicity."( Evaluation of thrombocytopenia in patients treated with rhenium-186-HEDP: guidelines for individual dosage recommendations.
Blijham, GH; de Klerk, JM; Han, SH; Stokkel, MP; van Dijk, A; van het Schip, AD; van Rijk, PP; Zonnenberg, BA, 1994
)
0.53
"Although the function of normal bone marrow is affected by metastases in patients with metastatic bone disease, the MIRD model can be used to relate toxicity to the bone marrow absorbed dose after a therapeutic dosage of 186Re-HEDP."( Bone marrow absorbed dose of rhenium-186-HEDP and the relationship with decreased platelet counts.
Blijham, GH; de Klerk, JM; Hoekstra, A; Rutgers, DH; van Dieren, EB; van Dijk, A; van het Schip, AD; van Rijk, PP; Zonnenberg, BA, 1996
)
0.59
" A Phase 1 dosage escalation study was performed using 186Re-HEDP in patients with metastatic breast cancer."( Phase 1 study of rhenium-186-HEDP in patients with bone metastases originating from breast cancer.
Blijham, GH; de Klerk, JM; Quirijnen, JM; van Dijk, A; van het Schip, AD; van Rijk, PP; Zonnenberg, BA, 1996
)
0.63
" This paper reports the results of dosage escalation studies with 186Re-HEDP as a bone-seeking radiopharmaceutical in patients with bone metastases originating from breast or prostate cancer with regard to toxicity, pharmacokinetics and bone marrow dosimetry and the palliating effect on bone pain."( Treatment of metastatic bone pain using the bone seeking radiopharmaceutical Re-186-HEDP.
Blijham, GH; De Klerk, JM; Han, SH; Hoekstra, A; Quirijnen, JM; Van Dijk, A; Van Het Schip, AD; Van Rijk, PP; Zonnenberg, BA,
)
0.13
"The goal of our studies was to determine whether administration of IL-1/GM-CSF to mice could reduce radio-antibody-induced myelosuppression and allow either dose escalation of radio-antibody using 131I, 90Y or 188Re conjugated to either intact antibody or bivalent fragments or more frequent dosing with 131I-IgG."( Application of cytokine intervention for improved radio-antibody dose delivery.
Behr, T; Blumenthal, RD; Goldenberg, DM; Haywood, L; Sharkey, RM, 1997
)
0.3
" No clear dose-response relationship was found."( 186Re-etidronate in breast cancer patients with metastatic bone pain.
Blijham, GH; de Klerk, JM; Han, SH; Quirijnen, JM; van Dijk, A; van het Schip, AD; van Rijk, PP; Zonneberg, BA, 1999
)
0.3
" Of the six patients treated at the highest dosage schedules (three at 1510 MBq/m2 and three at 1665 MBq/m2), three showed a posttherapy decline in prostate-specific antigen of 50% or more."( Rhenium-186-labeled hydroxyethylidene diphosphonate dosimetry and dosing guidelines for the palliation of skeletal metastases from androgen-independent prostate cancer.
Curley, T; Daghighian, F; Goldsmith, SJ; Graham, MC; Larson, SM; Liu, GB; Scher, HI; Yeh, SD, 1999
)
1.75
" However, if the balloon ruptures, 188Re-perrhenate is released into the circulation, causing high radiation dosing to the thyroid and stomach."( A comprehensive study on the blockage of thyroid and gastric uptakes of 188Re-perrhenate in endovascular irradiation using liquid-filled balloon to prevent restenosis.
Hsieh, JF; Knapp, FF; Lin, WY; Tsai, SC; Wang, SJ; Yen, TC, 2000
)
0.31
" Following a surface dosage of 45 Gy the proliferative response to the vessel injury is almost completely abolished."( Endovascular irradiation with the liquid beta-emitter Rhenium-188 to reduce restenosis after experimental wall injury.
Eble, M; Hanke, H; Hess, B; Höher, M; Hombach, V; Kamenz, J; Kotzerke, J; Reske, SN; Wohlfrom, M; Wöhrle, J, 2001
)
0.56
" However, by this new scintigraphic quantification method, bone uptake and soft-tissue retention can be calculated separately, thus providing more detailed kinetic data and potentially improving the dosimetry of these radiopharmaceuticals in, for example, assessment of radiation dosage to bone and bone marrow."( Skeletal uptake and soft-tissue retention of 186Re-HEDP and 153Sm-EDTMP in patients with metastatic bone disease.
Brenner, W; Henze, E; Kampen, AM; Kampen, WU, 2001
)
0.31
" In the absence of a positive dose-response relationship for the (188)Re-labeled antibody, the observation may be explained by an underestimation of the biologically effective dose and the inaccuracy of the dose determination at the glomerular level."( Enhanced renal toxicity of total body irradiation combined with radioimmunotherapy.
Bartkowiak, D; Bunjes, D; Dohr, D; Röttinger, EM; Wennauer, R, 2003
)
0.32
" The equivalent total-body dose was deduced from the DC yields using an in vitro dose-response curve."( Biologic dosimetry of 188Re-HDD/lipiodol versus 131I-lipiodol therapy in patients with hepatocellular carcinoma.
Bacher, K; de Ridder, L; De Ruyck, K; De Vos, F; Dierckx, RA; Gemmel, F; Lambert, B; Thierens, H; Vral, A, 2004
)
0.32
"Standardization of marrow dosimetry is of considerable importance when estimating dose-response for a multicentered clinical trial involving radionuclide therapy."( Bone marrow dosimetry using blood-based models for radiolabeled antibody therapy: a multiinstitutional comparison.
Bolch, WE; Bouchet, LG; Breitz, HB; Denardo, GL; Meredith, RF; Sgouros, G; Stabin, MG; Wessels, BW, 2004
)
0.32
" Methods of formatting the collection of standard datasets useful in defining dose-response parameters are also presented."( Bone marrow dosimetry using blood-based models for radiolabeled antibody therapy: a multiinstitutional comparison.
Bolch, WE; Bouchet, LG; Breitz, HB; Denardo, GL; Meredith, RF; Sgouros, G; Stabin, MG; Wessels, BW, 2004
)
0.32
" A parameter sensitivity analysis and a summary discussion of the use of this model for potentially improving dose-response data correlation are also presented."( Bone marrow dosimetry using blood-based models for radiolabeled antibody therapy: a multiinstitutional comparison.
Bolch, WE; Bouchet, LG; Breitz, HB; Denardo, GL; Meredith, RF; Sgouros, G; Stabin, MG; Wessels, BW, 2004
)
0.32
"In a previous study, we have described the elaboration of PLLA-based nanoparticles loaded with non radioactive dirhenium decacarbonyl [Re(2)(CO)(10)], a novel neutron-activatable radiopharmaceutical dosage form for intra-tumoral radiotherapy."( Dirhenium decacarbonyl-loaded PLLA nanoparticles: influence of neutron irradiation and preliminary in vivo administration by the TMT technique.
Canet-Soulas, E; Faraj, AA; Fessi, H; Hamoudeh, M; Mehier, H, 2008
)
1.28
" Cholangiocellular carcinoma cells (TFK-1 cells) were treated either with 8 Gy (RTB group) or 16 Gy (RTA group) (188)Re or with (188)Re irradiation (8 Gy) combined with either gemcitabine (8 Gy/Gem) or 5-fluorouracil (8 Gy/5-FU) at a dosage of 20 microg/ml medium for 4 days and subsequently compared with an untreated control group."( Impact of rhenium-188, gemcitabine, and 5-fluorouracil on cholangiocellular carcinoma cells: an in vitro study.
Bantleon, R; Farkas, E; Kehlbach, R; Werner, M; Wiesinger, B; Wiskirchen, J, 2009
)
0.76
" The introduction of the compound in dosage according to the scheme of antioxidant therapy, inhibited the tumor growth by ca."( Synthesis, characterization, in vivo antitumor properties of the cluster rhenium compound with GABA ligands and its synergism with cisplatin.
Collery, P; Domasevitch, KV; Golichenko, AA; Shtemenko, AV; Shtemenko, NI; Zabitskaya, ED, 2009
)
0.58
" Rats administered with ¹⁸⁸Re-BMEDA-liposome at dosage of 185 MBq displayed a significant weight loss compared with the control from study day (SD) 1 to SD 4, and the white blood cell count reduced to 5-10% of initial value (female: 18."( Preliminary evaluation of acute toxicity of (188) Re-BMEDA-liposome in rats.
Chang, CH; Chang, TJ; Chang, YJ; Chen, HL; Chen, LC; Chiang, TC; Ho, CL; Hsu, CW; Lee, TW; Liu, CM; Yu, CY, 2010
)
0.36
" The efficacy of MMF as an immunosuppressant and long-term safety in cats of this dosage regimen is unknown."(
Abrams, G; Adolfsson, E; Agarwal, PK; Akkan, AG; Al Alhareth, NS; Alves, VGL; Armentano, R; Bahroos, E; Baig, M; Baldridge, KK; Barman, S; Bartolucci, C; Basit, A; Bertoli, SV; Bian, L; Bigatti, G; Bobenko, AI; Boix, PP; Bokulic, T; Bolink, HJ; Borowiec, J; Bulski, W; Burciaga, J; Butt, NS; Cai, AL; Campos, AM; Cao, G; Cao, Y; Čapo, I; Caruso, ML; Chao, CT; Cheatum, CM; Chelminski, K; Chen, AJW; Chen, C; Chen, CH; Chen, D; Chen, G; Chen, H; Chen, LH; Chen, R; Chen, RX; Chen, X; Cherdtrakulkiat, R; Chirvony, VS; Cho, JG; Chu, K; Ciurlino, D; Coletta, S; Contaldo, G; Crispi, F; Cui, JF; D'Esposito, M; de Biase, S; Demir, B; Deng, W; Deng, Z; Di Pinto, F; Domenech-Ximenos, B; Dong, G; Drácz, L; Du, XJ; Duan, LJ; Duan, Y; Ekendahl, D; Fan, W; Fang, L; Feng, C; Followill, DS; Foreman, SC; Fortunato, G; Frew, R; Fu, M; Gaál, V; Ganzevoort, W; Gao, DM; Gao, X; Gao, ZW; Garcia-Alvarez, A; Garza, MS; Gauthier, L; Gazzaz, ZJ; Ge, RS; Geng, Y; Genovesi, S; Geoffroy, V; Georg, D; Gigli, GL; Gong, J; Gong, Q; Groeneveld, J; Guerra, V; Guo, Q; Guo, X; Güttinger, R; Guyo, U; Haldar, J; Han, DS; Han, S; Hao, W; Hayman, A; He, D; Heidari, A; Heller, S; Ho, CT; Ho, SL; Hong, SN; Hou, YJ; Hu, D; Hu, X; Hu, ZY; Huang, JW; Huang, KC; Huang, Q; Huang, T; Hwang, JK; Izewska, J; Jablonski, CL; Jameel, T; Jeong, HK; Ji, J; Jia, Z; Jiang, W; Jiang, Y; Kalumpha, M; Kang, JH; Kazantsev, P; Kazemier, BM; Kebede, B; Khan, SA; Kiss, J; Kohen, A; Kolbenheyer, E; Konai, MM; Koniarova, I; Kornblith, E; Krawetz, RJ; Kreouzis, T; Kry, SF; Laepple, T; Lalošević, D; Lan, Y; Lawung, R; Lechner, W; Lee, KH; Lee, YH; Leonard, C; Li, C; Li, CF; Li, CM; Li, F; Li, J; Li, L; Li, S; Li, X; Li, Y; Li, YB; Li, Z; Liang, C; Lin, J; Lin, XH; Ling, M; Link, TM; Liu, HH; Liu, J; Liu, M; Liu, W; Liu, YP; Lou, H; Lu, G; Lu, M; Lun, SM; Ma, Z; Mackensen, A; Majumdar, S; Martineau, C; Martínez-Pastor, JP; McQuaid, JR; Mehrabian, H; Meng, Y; Miao, T; Miljković, D; Mo, J; Mohamed, HSH; Mohtadi, M; Mol, BWJ; Moosavi, L; Mosdósi, B; Nabu, S; Nava, E; Ni, L; Novakovic-Agopian, T; Nyamunda, BC; Nyul, Z; Önal, B; Özen, D; Özyazgan, S; Pajkrt, E; Palazon, F; Park, HW; Patai, Á; Patai, ÁV; Patzke, GR; Payette, G; Pedoia, V; Peelen, MJCS; Pellitteri, G; Peng, J; Perea, RJ; Pérez-Del-Rey, D; Popović, DJ; Popović, JK; Popović, KJ; Posecion, L; Povall, J; Prachayasittikul, S; Prachayasittikul, V; Prat-González, S; Qi, B; Qu, B; Rakshit, S; Ravelli, ACJ; Ren, ZG; Rivera, SM; Salo, P; Samaddar, S; Samper, JLA; Samy El Gendy, NM; Schmitt, N; Sekerbayev, KS; Sepúlveda-Martínez, Á; Sessolo, M; Severi, S; Sha, Y; Shen, FF; Shen, X; Shen, Y; Singh, P; Sinthupoom, N; Siri, S; Sitges, M; Slovak, JE; Solymosi, N; Song, H; Song, J; Song, M; Spingler, B; Stewart, I; Su, BL; Su, JF; Suming, L; Sun, JX; Tantimavanich, S; Tashkandi, JM; Taurbayev, TI; Tedgren, AC; Tenhunen, M; Thwaites, DI; Tibrewala, R; Tomsejm, M; Triana, CA; Vakira, FM; Valdez, M; Valente, M; Valentini, AM; Van de Winckel, A; van der Lee, R; Varga, F; Varga, M; Villarino, NF; Villemur, R; Vinatha, SP; Vincenti, A; Voskamp, BJ; Wang, B; Wang, C; Wang, H; Wang, HT; Wang, J; Wang, M; Wang, N; Wang, NC; Wang, Q; Wang, S; Wang, X; Wang, Y; Wang, Z; Wen, N; Wesolowska, P; Willis, M; Wu, C; Wu, D; Wu, L; Wu, X; Wu, Z; Xia, JM; Xia, X; Xia, Y; Xiao, J; Xiao, Y; Xie, CL; Xie, LM; Xie, S; Xing, Z; Xu, C; Xu, J; Yan, D; Yan, K; Yang, S; Yang, X; Yang, XW; Ye, M; Yin, Z; Yoon, N; Yoon, Y; Yu, H; Yu, K; Yu, ZY; Zhang, B; Zhang, GY; Zhang, H; Zhang, J; Zhang, M; Zhang, Q; Zhang, S; Zhang, W; Zhang, X; Zhang, Y; Zhang, YW; Zhang, Z; Zhao, D; Zhao, F; Zhao, P; Zhao, W; Zhao, Z; Zheng, C; Zhi, D; Zhou, C; Zhou, FY; Zhu, D; Zhu, J; Zhu, Q; Zinyama, NP; Zou, M; Zou, Z, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
manganese group element atom
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (1,993)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990133 (6.67)18.7374
1990's189 (9.48)18.2507
2000's785 (39.39)29.6817
2010's746 (37.43)24.3611
2020's140 (7.02)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 82.33

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index82.33 (24.57)
Research Supply Index7.70 (2.92)
Research Growth Index4.95 (4.65)
Search Engine Demand Index149.19 (26.88)
Search Engine Supply Index2.01 (0.95)

This Compound (82.33)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials111 (5.27%)5.53%
Reviews114 (5.41%)6.00%
Case Studies45 (2.14%)4.05%
Observational3 (0.14%)0.25%
Other1,833 (87.04%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]